IL-1β centrality via canakinumab trial

Key Findings

• ●IL-1β centrality demonstrated
• ●PBMCs hyperresponsive to LPS

Referenced in (1 disease)

1. passsource metadataJun 1, 2026, 04:40 PMby pubmed-api

   Stored DOI was incorrect; corrected to the PubMed-registered DOI (verified to resolve to this article).

   tools: pubmed.esummary, crossref.works